LoginSignup
Genmab logo

Genmab Stock

StockStock
ISIN: DK0010272202
Ticker: GMAB
DK0010272202
GMAB

Price

Frequently asked questions

What is Genmab's market capitalization?

The market capitalization of Genmab is $14.52B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Genmab's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Genmab is 21.74. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Genmab?

Genmab's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $10.10. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Genmab's stock?

Currently, 24 analysts cover Genmab's stock, with a consensus target price of $377.39. Analyst ratings provide insights into the stock's expected performance.

What is Genmab's revenue over the trailing twelve months?

Over the trailing twelve months, Genmab reported a revenue of $2.80B.

What is the EBITDA for Genmab?

Genmab's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $957.33M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Genmab?

Genmab has a free cash flow of $928.05M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Genmab's stock?

The 5-year beta for Genmab is 1.14. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Genmab have, and what sector and industry does it belong to?

Genmab employs approximately 2,635 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Genmab's shares?

The free float of Genmab is 63.50M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $14.52B

5Y beta

 1.14

EPS (TTM)

 $10.10

Free Float

 63.50M

P/E ratio (TTM)

 21.74

Revenue (TTM)

 $2.80B

EBITDA (TTM)

 $957.33M

Free Cashflow (TTM)

 $928.05M

Pricing

1D span
$217.83$225.11
52W span
$259.37$325.81

Analyst Ratings

The price target is $377.39 and the stock is covered by 24 analysts.

Buy

13

Hold

7

Sell

4

Information

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

2,635

Biotechnology & Drugs

Health Care

Identifier

ISIN

DK0010272202

Primary Ticker

GMAB

Knockouts

Join the conversation
Sign upLogin